Dr. Eytan Stein on Multiple Targets in Acute Myeloid Leukemia

preview_player
Показать описание
Eytan Stein, MD, hematologist/oncologist, Memorial Sloan Kettering Cancer Center, discusses targeting multiple mutations in patients with acute myeloid leukemia (AML).

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
Dr. Eytan Stein 0:01:08

Dr. Eytan Stein on Multiple Targets in Acute Myeloid Leukemia

Dr. Eytan Stein 0:01:11

Dr. Eytan Stein on Novel Combinations in AML

Dr. Eytan Stein 0:01:19

Dr. Eytan Stein on Targeting Mutations in Acute Myeloid Leukemia

Personalized Medicine for 1:02:03

Personalized Medicine for Your Acute Myeloid Leukemia | Dr. Eytan Stein #AML

High-Risk MDS/AML: Genomic-Driven 0:05:15

High-Risk MDS/AML: Genomic-Driven Approaches from ASH19 - Eytan Stein, MD

ASH Impact Series: 0:05:04

ASH Impact Series: Eytan Stein, MD - Latest Developments in Targeted Therapies for AML

EHA 2022 | 0:02:36

EHA 2022 | Eytan Stein | Tamibarotene and Lanraplenib (LANRA) Updates for Acute Myeloid Leukemia

Treating MDS in 0:55:51

Treating MDS in Young Adults

New Therapies in 0:02:13

New Therapies in AML - Menin Inhibitor Revumenib (SNDX-5613) | Eytan M. Stein, MD | ASH 2022 #AML

Toxicity profiles of 0:01:24

Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?

Therapeutic targeting of 0:01:25

Therapeutic targeting of splicing factor mutations in myeloid malignancies

Eytan M. Stein, 0:05:52

Eytan M. Stein, MD: Enasidenib Shows 'Encouraging' Efficacy in IDH2-Mutated AML

Toxicity prevention and 0:00:57

Toxicity prevention and management when using revumenib for the treatment of AML

What Are Current 0:07:43

What Are Current and Emerging AML Treatment Approaches?

Tips for Thriving 0:03:29

Tips for Thriving With AML | Setting Treatment Goals

Blood Cancer Awareness 0:08:28

Blood Cancer Awareness - Acute Myeloid Leukemia (AML)

Disease Monitoring: Is 0:02:38

Disease Monitoring: Is My AML Treatment Working?

Considerations When Choosing 0:03:18

Considerations When Choosing an AML Treatment

How to optimally 0:01:45

How to optimally manage relapse in AML

Menin Inhibitors are 0:02:24

Menin Inhibitors are on the Horizon for NPM1 Mutated AML | Eytan Stein | ASH 2021 #AML

Primary and secondary 0:02:38

Primary and secondary resistance in AML

Prolonging survival in 0:00:46

Prolonging survival in patients with AML ineligible for intensive chemotherapy

Tamibarotene combined with 0:00:47

Tamibarotene combined with azacitidine and venetoclax to treat AML and MDS with RARA abnormalities

Phase I study 0:07:15

Phase I study shows AG-221 induces durable remissions in IDH2-mutant acute myeloid leukaemia

welcome to shbcf.ru